Clinical trial
Replagal Enzyme Replacement Therapy for Adults With Fabry Disease
NCT00097890 · National Institute of Neurological Disorders and Stroke (NINDS), NIH · Completed
Key facts
| NCT number | NCT00097890 |
|---|---|
| Title | Replagal Enzyme Replacement Therapy for Adults With Fabry Disease |
| Official title | An Open Label Six-Month Maintenance Clinical Trial of Replagal Enzyme Replacement Therapy in Patients With Fabry Disease Who Have Completed TKT027 |
| Lead sponsor | National Institute of Neurological Disorders and Stroke (NINDS), NIH |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Fabry Disease |
| Intervention type | Drug |
| Interventions | Replagal (Agalsidase Alfa), Replagal |
| Enrollment | 25 |
| Start date | Nov 1, 2004 |
| Completion | Dec 1, 2005 |
| First posted | Dec 1, 2004 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: